Cystic Fibrosis

CTAF

This is the most recent cystic fibrosis assessment. To see the previous cystic fibrosis assessment, click here.

ICER’s report will focus on elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals). ICER also will examine any new data that has become available since its May 2018 review of three other CF treatments already approved by the FDA: tezacaftor/ivacaftor (Symdeko®, Vertex), lumacaftor/ivacaftor (Orkambi®, Vertex), and ivacaftor (Kalydeco®, Vertex).

Associated Meetings

April 30, 2020 10am-4pm ET

TBA

The California Technology Assessment Forum (CTAF) will convene to deliberate and vote on evidence presented in ICER's report on treatments for cystic fibrosis.


Key Dates

Associated Materials

09/06/2019 – 09/25/2019
Open Input Period

09/30/2019
Draft Scoping Document

09/30/2019 – 10/21/2019
Public Comments

09/30/2019

10/29/2019
Revised Scoping Document

12/05/2019
Research Protocol

01/06/2020
Model Analysis Plan

02/20/2020
Draft Evidence Report

02/20/2020
Draft Voting Questions

02/20/2020 – 03/18/2020
Public Comments

04/09/2020
Revised Voting Questions

04/09/2020
Response to Public Comments

04/09/2020
Meeting Agenda

04/09/2020
Evidence Report

04/09/2020
Evidence Presentation

05/21/2020
Final Evidence Report and Meeting Summary

05/21/2020
Report-at-a-Glance

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
May 17, 2018 9:30am-3:30pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to discuss treatments for cystic fibrosis.

Key Dates

Associated Materials